Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Non-Current Assets: 2022-2024

Historic Non-Current Assets for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $1.3 million.

  • Corvus Pharmaceuticals' Non-Current Assets fell 25.11% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 25.11%. This contributed to the annual value of $1.3 million for FY2024, which is 7.78% down from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Non-Current Assets stood at $1.3 million for FY2024, which was down 7.78% from $1.4 million recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Non-Current Assets ranged from a high of $1.7 million in FY2022 and a low of $1.3 million during FY2024.
  • For the 3-year period, Corvus Pharmaceuticals' Non-Current Assets averaged around $1.5 million, with its median value being $1.4 million (2023).
  • Data for Corvus Pharmaceuticals' Non-Current Assets shows a maximum YoY decreased of 13.62% (in 2023) over the last 5 years.
  • Over the past 3 years, Corvus Pharmaceuticals' Non-Current Assets (Yearly) stood at $1.7 million in 2022, then fell by 13.62% to $1.4 million in 2023, then fell by 7.78% to $1.3 million in 2024.